RPS27L and breast cancer: We found that RPS27L silencing remarkably inhibited the activity of mTORC1, but not mTORC2, in breast cancer cells and MEFs, as evidenced by reduced phosphorylation levels of their downstream effectors as well as direct in vitro kinase activity assays (Figs. 2 and 3).